Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review

Abstract Chronic inflammation is an underlying feature of respiratory diseases such as chronic obstructive pulmonary disease (COPD). Novel therapies that target the inflammatory mechanisms driving acute exacerbations of COPD are required. The ST2 receptor, which binds the alarmin interleukin (IL)-33...

Description complète

Détails bibliographiques

Auteurs principaux:	Steven G. Kelsen, Marcus Maurer, Michael Waters, Ajit Dash, Alice Fong, Divya Mohan, Wiebke Theess, Xiaoying Yang, Giuseppe Alvaro, Christopher E. Brightling
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-10-01
Collection:	Respiratory Research
Sujets:	Astegolimab Asthma Chronic obstructive pulmonary disease Interleukin-33 (IL-33) Infection Inflammation
Accès en ligne:	https://doi.org/10.1186/s12931-025-03360-0
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!